<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723060</url>
  </required_header>
  <id_info>
    <org_study_id>11769A</org_study_id>
    <nct_id>NCT00723060</nct_id>
  </id_info>
  <brief_title>Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder</brief_title>
  <official_title>Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: The objective of this study is to compare the effect and safety of conventional
      dose (20mg) and high dose (40mg) of escitalopram in patients with obsessive-compulsive
      disorder (OCD).

      OVERVIEW OF STUDY DESIGN: Prospective, Randomized, Active-controlled, Double-blind,
      Multi-center, Clinical Trials STUDY POPULATION: Patients with OCD EFFICACY EVALUATIONS:
      Y-BOCS (D-YBOCS), HAM-D, HAM-A, CGI-S &amp; -I, GAF, OCI-R SAFETY EVALUATION: Adverse Events /
      Serious Adverse Events, UKU
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of Y-BOCS score average from baseline to 16-week</measure>
    <time_frame>baseline and16-week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) CGI-S, CGI-I 2) GAF 3) HAM-D, HAM-A</measure>
    <time_frame>every 2 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>escitalopram high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>escitalopram conventional group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man or woman, aged 18 to 65 years, outpatient

          2. Primary OCD patients diagnosed with DSM-IV-TR, having OCD symptoms for more than six
             months

          3. Severity: Y-BOCS score of &gt;= 20 at screening and baseline

          4. No history or evidences of clinically significant physical problem, or abnormal
             laboratory findings at screening

          5. Drug free period of at least 2 weeks before study drug administration (in case of
             fluoxetine, at least 5 weeks). However, allowed medications in this study could be
             taken even before study drug administration.

        Exclusion Criteria:

          1. primary active DSM-IV axis I diagnosis other than OCD

          2. History of substance, including alcohol, dependence and psychotic symptoms

          3. Current depression A. Risk of suicidal attempt B. 20-item Hamilton Depression Rating
             Scale (HAM-D)(exclude 21th item, obsession) of &gt;17 at screening or baseline

          4. Drug allergy A. Known or suspected hypersensitivity to escitalopram or citalopram B.
             History of severe drug allergic reactions or hypersensitivity

          5. History of no response to escitalopram or citalopram treatment

          6. History of electroconvulsive therapy or received an injectable antipsychotic
             formulation within 6 months before screening

          7. Women who are pregnant, planning to become pregnant, or breast-feeding

          8. Ongoing cognitive behavior therapy (CBT) of OCD

          9. Hoarding or collecting type

         10. Unable to perform study protocol as clinically assessed by the investigator (ex,
             severe personality disorder)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Soo Kwon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <last_update_submitted>August 5, 2011</last_update_submitted>
  <last_update_submitted_qc>August 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Seoul National University Hospital</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

